(Q59650414)

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Genetic and pharmacological analysis of prostanoid receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Prostaglandin and thromboxane biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Cyclooxygenase-2 and its regulation in inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

The coxibs, selective inhibitors of cyclooxygenase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear str

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Platelet activation in unstable coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Acetylation of prostaglandin synthase by aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Aspirin as an antiplatelet drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Altered pain perception and inflammatory response in mice lacking prostacyclin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Lipid peroxidation and platelet activation in murine atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Risk of cardiovascular events associated with selective COX-2 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902234-8